The Regional Scientific Director establishes trusted partnerships with healthcare professionals to provide scientific education on CRISPR-based gene editing programs. They also support Phase 3 clinical trial activities, including site activation, recruitment, and addressing operational barriers.
The Strategic Account Liaison will lead site assessment, readiness, and activation strategies to ensure treatment centers can successfully administer CRISPR-based therapies. This role involves managing complex care pathways, coordinating with healthcare providers, and navigating reimbursement processes to ensure seamless patient access.
The role is responsible for setting and executing the integrated evidence strategy to demonstrate value and enable durable access for gene editing therapies. This includes leading the Field HEOR team to drive payer engagement and informing U.S. coverage and reimbursement decisions.
Lead strategic engagement with national and regional commercial payers to secure favorable coverage and reimbursement for gene editing therapies. Collaborate cross-functionally to develop value propositions, pricing strategies, and account plans for product launch.
Lead the strategic transformation of the Quality Management System and digital compliance footprint to support commercialization. Oversee global quality governance, risk management, and the management of a high-performing team of quality professionals.
Define and execute the enterprise-wide quality vision and strategy to support growth from clinical development through commercial operations. Lead digital transformation through eQMS implementation and ensure global regulatory compliance and inspection readiness.
The role involves building the commercial FP&A infrastructure, including sophisticated revenue models and gross-to-net frameworks for a pre-revenue biotech. The Director will partner with Commercial and Access teams to manage launch strategy spend and provide revenue projections to the C-suite.
